alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# L_2019207EN.01003601.xml

| 7.8.2019 | EN | Official Journal of the European Union | L 207/36 |
| --- | --- | --- | --- |

7.8.2019

EN

Official Journal of the European Union

L 207/36

---

EUROPEAN COUNCIL DECISION (EU) 2019/1330

of 5 August 2019

appointing the High Representative of the Union for Foreign Affairs and Security Policy

THE EUROPEAN COUNCIL,

Having regard to the Treaty on European Union, and in particular Article 18(1) thereof,

Whereas:

| (1) | European Council Decision 2014/639/EU (1) appointed the High Representative of the Union for Foreign Affairs and Security Policy until 31 October 2019. |
| --- | --- |

(1)

European Council Decision 2014/639/EU (1) appointed the High Representative of the Union for Foreign Affairs and Security Policy until 31 October 2019.

| (2) | The High Representative of the Union for Foreign Affairs and Security Policy should be appointed for the period from the end of the current term of office of the Commission until 31 October 2024. |
| --- | --- |

(2)

The High Representative of the Union for Foreign Affairs and Security Policy should be appointed for the period from the end of the current term of office of the Commission until 31 October 2024.

| (3) | By letter of 26 July 2019, the President-elect has agreed to the appointment of Mr Josep BORRELL FONTELLES as High Representative of the Union for Foreign Affairs and Security Policy. |
| --- | --- |

(3)

By letter of 26 July 2019, the President-elect has agreed to the appointment of Mr Josep BORRELL FONTELLES as High Representative of the Union for Foreign Affairs and Security Policy.

| (4) | In accordance with the third subparagraph of Article 17(7) of the Treaty on European Union, the President, the High Representative of the Union for Foreign Affairs and Security Policy and the other members of the Commission are subject as a body to a vote of consent by the European Parliament, |
| --- | --- |

(4)

In accordance with the third subparagraph of Article 17(7) of the Treaty on European Union, the President, the High Representative of the Union for Foreign Affairs and Security Policy and the other members of the Commission are subject as a body to a vote of consent by the European Parliament,

HAS ADOPTED THIS DECISION:

Article 1

Mr Josep BORRELL FONTELLES is hereby appointed High Representative of the Union for Foreign Affairs and Security Policy for the period from the end of the current term of office of the Commission until 31 October 2024.

Article 2

This Decision shall be notified to Mr Josep BORRELL FONTELLES by the President of the European Council.

It shall take effect on the day of its notification.

Article 3

This Decision shall be published in the Official Journal of the European Union.

Done at Brussels, 5 August 2019.

For the European Council

The President

D. TUSK

---

(1)  European Council Decision 2014/639/EU of 30 August 2014 appointing the High Representative of the Union for Foreign Affairs and Security Policy (OJ L 262, 2.9.2014, p. 6).

1

---
§ 582.5065 Linoleic acid. ( a ) *Product.* Linoleic acid prepared from edible fats and oils and free from chick-edema factor.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 520.2520a Trichlorfon and atropine. ( a ) *Specifications.* ( 1 ) For trichlorfon: O,O-Dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate.
( 2 ) For atropine: Atropine N.F.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in mice* — ( 1 ) *Amount.* Administer 1.67 grams of trichlorfon and 7.7 milligrams of atropine per liter continuously for 7 to 14 days as the sole source of drinking water.
( 2 ) *Indications for use.* For the treatment of *Syphacia obvelata* (pinworm) in laboratory mice.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28832, May 20, 2014]
# C_2015056EN.01001001.xml

| 16.2.2015 | EN | Official Journal of the European Union | C 56/10 |
| --- | --- | --- | --- |

16.2.2015

EN

Official Journal of the European Union

C 56/10

---

Request for a preliminary ruling from the Juzgado Contencioso-Administrativo No 6 de Murcia (Spain) lodged on 3 December 2014 — IOS Finance EFC SA v Servicio Murciano de Salud

o

(Case C-555/14)

(2015/C 056/12)

Language of the case: Spanish

Referring court

Referring court

Juzgado Contencioso-Administrativo No 6 de Murcia

o

Parties to the main proceedings

Parties to the main proceedings

Applicant: IOS Finance EFC SA

Applicant:

Defendant: Servicio Murciano de Salud

Defendant:

Questions referred

Questions referred

‘‘Regard being had to Articles 4(1), 6 and 7(2) and (3) of Directive 2011/7/EU of the European Parliament and of the Council of 16 February 2011 (1) on combating late payment in commercial transactions:

1

| 1) | Must Article 7(2) of the directive be interpreted as meaning that a Member State may not make recovery of the principal debt conditional on the waiver of the right to interest for late payment? |
| --- | --- |

1)

Must Article 7(2) of the directive be interpreted as meaning that a Member State may not make recovery of the principal debt conditional on the waiver of the right to interest for late payment?

| 2) | Must Article 7(3) of the directive be interpreted as meaning that a Member State may not make recovery of the principal debt conditional on the waiver of the right to compensation for recovery costs? |
| --- | --- |

2)

Must Article 7(3) of the directive be interpreted as meaning that a Member State may not make recovery of the principal debt conditional on the waiver of the right to compensation for recovery costs?

| 3) | Should the answer to those two questions be in the affirmative, where the debtor is a contracting authority, can it rely on the freedom of contract of the parties in order to avoid its obligation to pay interest for late payment and compensation for recovery costs?’ |
| --- | --- |

3)

Should the answer to those two questions be in the affirmative, where the debtor is a contracting authority, can it rely on the freedom of contract of the parties in order to avoid its obligation to pay interest for late payment and compensation for recovery costs?’

---

(1)  OJ 2011 L 48, p. 1.

1

---
Exhibit



                                               Motorola Solutions, Inc.
2017-2019 Long Range Incentive Plan (LRIP) Terms
As Approved by the Compensation and Leadership Committee On February 16, 2017







Exhibit 10.1
	
					
	Design Feature
	2017-2019 LRIP

	Performance Cycle
	Three years from January 1, 2017 through December 31, 2019

	Eligible Population
	Corporate Vice Presidents and above

	Performance Criteria
	

Relative Total Shareholder Return (TSR)
TSR Defined as:
Ending stock price
   (Daily average during the final three months of the Performance Cycle)
+   Value of reinvested dividends
=   Total ending value
–   Beginning stock price
   (Daily average during the three months preceding the Performance Cycle)
=   Total value created
÷   Beginning share price
   (Daily average during the three months preceding the Performance Cycle)
= Total shareholder return



	Negative TSR Component
	If the resulting TSR performance for Motorola Solutions is negative, the Committee will have negative discretion to reduce the final payout up to a 25% reduction of the calculated payout.

	Comparator Group
	S&P 500 defined as companies in the S&P 500 at the beginning of the performance period; must be publicly traded on or after July 1, 2018 to be included in the TSR percentile calculation at the end of the performance cycle.

	Payout Scale




	 

	 
	Relative TSR Payout Scale
	 

	MSI 3-Year TSR Percentile Rank
	Payout Factor

	90th - 100th Percentile
	250%

	80th - 89.99th Percentile
	200%

	70th - 79.99th Percentile
	175%

	60th - 69.99th Percentile
	150%

	55th - 59.99th Percentile
	110%

	50th - 54.99th Percentile
	90%

	45th - 49.99th Percentile
	80%

	35th - 44.99th Percentile
	50%

	30th - 34.99th Percentile
	30%

	< 30.99th Percentile
	0%
#### Harborcreek Township School District v. Bennett

*George W. Schroeck,*for appellant.

*Robert J. Firman*and *William W. Knox,*for appellee.

May 3, 1951.

Evans, P., J.,

— This matter is before us on a motion to quash a writ of certiorari and a motion for affirmance of the judgment of a justice of the peace.

From the transcript of Oscar N. Dick, justice of the peace in Harborcreek Township, Erie County, Pa., we find that an information was made against defendant charging him with violation of an ordinance by the School District of Harborcreek Township requiring residents of that township to file income tax returns to the receiver of taxes for the township. It further appears from the transcript that witnesses were called to show that defendant was a resident of the township and was regularly employed during the taxable period at the General Electric Company in Erie County and received earnings for such employment. Defendant claimed that the justice of the peace had no jurisdiction *262in the matter and therefore offered no testimony. He was adjudged guilty as charged, and fined $50 and costs.

On November 15, 1950, defendant appeared with bondsman and furnished bail in the amount of $300, stating his intention of taking an appeal. The transcript of the justice of the peace was mailed to the office of the District Attorney of Erie County on November 24, 1950, and thereafter was returned by the District Attorney on November 28,1950, for the reason that the appeal had not been perfected by a petition to the Court of Quarter Sessions for allowance thereof. On December 2, 1950, defendant, by attorney, filed a praecipe for certiorari in the office of the Prothonotary of the Common Pleas Court following which a transcript showing the facts as above recited was filed in the office of the prothonotary. A motion to quash the writ was filed December 7, 1950, and a motion for affirmance of the judgment of the justice of the peace was filed January 15,1951. Each of these motions set forth reasons therefor.

A special allowance from the Court of Common Pleas is necessary for a writ of certiorari to a justice of the peace in a criminal case: Commonwealth v. Antone, 22 Pa. Superior Ct. 412.

In our opinion this is an offense against the public and therefore criminal in character as distinguished from a violation of an ordinance the penalty for which is in the nature of a civil action for the recovery of damages.

The requirement of a special allowance of the Common Pleas Court for a writ of certiorari in such cases is to prevent the use of the writ for purposes of delay: Commonwealth v. Antone, supra.

If, as contended by defendant, this action is civil in nature, the rules granted on the motions before us must nevertheless be made absolute because of de*263fendant’s failure to file exceptions by the fourth day of the same week that the writ was sued out, as required by section 4 of rule 12 of our rules of court.

And now, to wit, May 3, 1951, the rule granted December 7,1950, on the motion to quash, and the rule granted January 15,1951, on the motion for affirmance of the judgment of the justice of the peace, are made absolute.
§ 556.580 Robenidine. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for robenidine are: ( 1 ) *Chickens.* ( i ) Skin and fat: 0.2 ppm.
( ii ) Other edible tissues (excluding eggs): 0.1 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See § 558.515 of this chapter.
<PAGE>



                                                                  EXHIBIT 32 (a)


     CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Northland Cable Properties Seven
Limited Partnership (the "Partnership") on Form 10Q for the period ended
September 30, 2004 as filed with the Securities and Exchange Commission on the
date hereof (the "Form 10-Q"), I, John Whetzell, Chief Executive Officer of
Northland Communications Corporation, the General Partner, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that;


          (1)  The Form 10-Q fully complies with the requirements of Section 13
               (a) or (15(d) of the Securities Exchange Act of 1934 (15 U.S.C.
               78m or 78(d)); and


          (2)  The information contained in the Form 10-Q fairly presents in all
               material respects, the financial condition and results of
               operations of the Partnership.


DATE: 11-12-04


/s/ JOHN S. WHETZELL
    ----------------
    John S. Whetzell
    Chief Executive Officer


A signed original of this written statement required by Section 906 has been
provided to Northland Cable Properties Seven Limited Partnership and will be
retained by Northland Cable Properties Seven Limited Partnership and furnished
to the Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED INTERIM DECEMBER 31, 1998 BALANCE SHEET AND STATEMENT OF OPERATIONS OF
FORCENERGY INC FOR THE YEAR ENDED DECEMBER 31, 1998 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                           1,690
<SECURITIES>                                         0
<RECEIVABLES>                                   28,433
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                49,791
<PP&E>                                         610,948
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 678,468
<CURRENT-LIABILITIES>                          778,720
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           247
<OTHER-SE>                                    (100,499)
<TOTAL-LIABILITY-AND-EQUITY>                   678,468
<SALES>                                        272,410
<TOTAL-REVENUES>                               273,549
<CGS>                                                0
<TOTAL-COSTS>                                  541,538
<OTHER-EXPENSES>                                (1,572)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              48,077
<INCOME-PRETAX>                               (314,494)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (314,494)
<EPS-BASIC>                                   (12.65)
<EPS-DILUTED>                                   (12.65)


</TABLE>
§ 520.2611 Trimethoprim and sulfadiazine paste. ( a ) *Specifications.* Each gram (g) of paste contains 67 milligrams (mg) trimethoprim and 333 mg sulfadiazine.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter: ( 1 ) No. 054771 for product administered as in paragraph (c)(1)(i) of this section.
( 2 ) No. 000061 for product administered as in paragraph (c)(1)(ii) of this section.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer orally as a single daily dose for 5 to 7 days: ( i ) 5 g of paste (335 mg trimethoprim and 1,665 mg sulfadiazine) per 150 pounds (68 kilograms) of body weight per day.
( ii ) 3.75 g of paste (250 mg trimethoprim and 1,250 mg sulfadiazine) per 110 pounds (50 kilograms) of body weight per day.
( 2 ) *Indications for use.* For use where systemic antibacterial action against sensitive organisms is required during treatment of acute strangles, respiratory infections, acute urogenital infections, and wound infections and abscesses.
( 3 ) *Limitations.* Not for use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 30802, May 31, 2006, as amended at 79 FR 28834, May 20, 2014]
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 07-1685

MILDRED BIH NGANG,

Petitioner,

v.

MICHAEL B. MUKASEY, Attorney General,

Respondent.

On Petition for Review of an Order of the Board of Immigration

Appeals. (A96-289-589)

Submitted: February 29, 2008 Decided: March 12, 2008

Before MOTZ and SHEDD, Circuit Judges, and HAMILTON, Senior Circuit

Judge.

Petition denied by unpublished per curiam opinion.

Peter Nyoh, PETER NYOH AND ASSOCIATES, Silver Spring, Maryland, for

Petitioner. Jeffrey S. Bucholtz, Assistant Attorney General,

Linda S. Wernery, Assistant Director, Erica B. Miles, OFFICE OF

IMMIGRATION LITIGATION, Washington, D.C., for Respondent.

Unpublished opinions are not binding precedent in this circuit.
- 2 -

PER CURIAM:

Mildred Bih Ngang, a native and citizen of Cameroon,

seeks review of an order of the Board of Immigration Appeals

(Board) denying her second motion to reopen removal proceedings.

We have reviewed the record and Ngang’s claims and conclude that

the Board did not abuse its discretion in denying Ngang’s motion.

See 8 C.F.R. § 1003.2(a), (c) (2007). 

We accordingly deny the petition for review. We dispense

with oral argument because the facts and legal contentions are

adequately presented in the materials before the court and argument

would not aid the decisional process.

PETITION DENIED
<PAGE> 91

                     WILLIAMS & WEBSTER, P.S.
                   Certified Public Accountants
                       601 West Riverside 
                            Suite 1970
                 Spokane, Washington   99201-0611
                          (509) 838-8111
                        FAX (509) 624-5001




             CONSENT OF CERTIFIED PUBLIC ACCOUNTANTS


Board of Directors 
SafeScience, Inc.
Boston, Massachusetts 


We consent to the use of our audit report dated March 27, 
1997, on the consolidated financial statements of IGG
International, Inc. as (now known as SafeScience, Inc.) 
as of December 31, 1996, for the filing with and attachment to
the Form 10-K for the year ending December 31, 1997, and the 
inclusion in the Company's previously filed Registration
Statement File Nos. 333-04764.

/s/ Williams & Webster P.S.

Williams & Webster, P.S.
Spokane, Washington 

March 30, 1998
Editorial Note on Part 570
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 570.220 General requirements applicable to a GRAS notice. ( a ) A GRAS notice has seven parts as required by §§ 570.225 through 570.255. You must submit the data and information specified in each of these parts on separate pages or sets of pages.
( b ) You must include each of the seven parts in your GRAS notice. If you do not include a part, you must include with your GRAS notice an explanation of why that part does not apply to your GRAS notice.
EXHIBIT 32.2
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                   AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection  with the  quarterly  report of Avitar,  Inc.  (the  "Company") on
Form10-QSB  for the period ending June 30, 2004 as filed with the Securities and
Exchange  Commission on the date hereof (the  "Report"),  I, Jay C.  Leatherman,
Jr.,  Chief  Financial  Officer of the  Company  certify,  pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002, to my knowledge, that:

     (1) The Report  fully  complies  with the  requirements  of  Section  13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Date: August 18, 2004

                                   /s/ Jay C. Leatherman, Jr.
                                  -------------------------
                                  Jay C. Leatherman, Jr.
                                  Chief Financial Officer (Principal Financial
                                  and Accounting Officer), Secretary
§ 520.302 Carnidazole tablets. ( a ) *Specifications.* Each tablet contains 10 milligrams of carnidazole.
( b ) *Sponsor.* See 053923 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Adult pigeons: 1 tablet (10 milligrams); newly weaned pigeons: 1 ⁄ 2 tablet (5 milligrams).
( 2 ) *Indications for use.* For treating trichomoniasis (canker) in ornamental and homing pigeons.
( 3 ) *Limitations.* Not for use in pigeons intended for human food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism or when severely ill birds do not respond to treatment.
[54 FR 32336, Aug. 7, 1989. Redesignated at 80 FR 13229, Mar. 13, 2015]
Editorial Note on Part 60
Editorial Note: Nomenclature changes to part 60 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 60.28 Time frame for determining regulatory review periods. ( a ) FDA will determine the regulatory review period for a product within 30 days of the receipt of a written request from PTO for such a determination and a copy of the patent term restoration application.
( b ) FDA may extend the 30-day period if: ( 1 ) A related FDA action that may affect the regulatory review period determination is pending; or
( 2 ) PTO requests that FDA temporarily suspend the determination process; or
( 3 ) PTO or FDA receives new information about the product that warrants an extension of the time required for the determination of the regulatory review period.
( c ) This section does not apply to applications withdrawn by the applicant or applications that PTO determines are ineligible for patent term restoration.